氙气对动脉瘤性蛛网膜下腔出血患者脑损伤、神经功能结局及生存的影响——一项随机临床试验的研究方案
本研究为前瞻性、多中心、II期、单盲、优势性随机两臂平行随访药物临床试验,旨在探索症状性动脉瘤性蛛网膜下腔出血(aSAH)发病6小时内吸入氙气的潜在神经保护作用。主要终点为通过脑磁共振弥散张量成像评估的全局白质损伤程度。研究指出过去10年aSAH死亡率和残疾率几乎未变,需要新的神经保护策略。
要点
- aSAH患者死亡和永久残疾风险高,影响人群较缺血性卒中年轻。
- 临床前研究显示氙气具有神经保护特性,院外心脏骤停后氙气可减轻白质损伤。
- 本II期试验在aSAH症状发作6小时内给予吸入氙气,以弥散张量成像评估白质损伤。
核心结论
- 研究旨在探索aSAH症状发作6小时内吸入氙气的潜在神经保护作用,主要终点为磁共振弥散张量成像评估的全局白质损伤程度。
研究设计与样本
- 前瞻性、多中心II期临床药物试验,采用单盲、优势性随机两臂平行随访设计,试验注册号ClinicalTrials.gov NCT04696523(2021年1月6日注册)及EudraCT 2019-001542-17(2020年7月8日注册)。
主要发现
- 原文未报告本研究的结果数据,仅报告研究方案及背景依据。
关键数值与推荐
- 主要终点为脑磁共振弥散张量成像评估的全局白质损伤程度,干预时机为aSAH症状发作后6小时内吸入氙气。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) is a neurological emergency, affecting a younger population than individuals experiencing an ischemic stroke; aSAH is associated with a high risk of mortality and permanent disability. The noble gas xenon has been shown to possess neuroprotective properties as demonstrated in numerous preclinical animal studies. In addition, a recent study demonstrated that xenon could attenuate a white matter injury after out-of-hospital cardiac arrest. METHODS: The study is a prospective, multicenter phase II clinical drug trial. The study design is a single-blind, prospective superiority randomized two-armed parallel follow-up study. The primary objective of the study is to explore the potential neuroprotective effects of inhaled xenon, when administered within 6 h after the onset of symptoms of aSAH. The primary endpoint is the extent of the global white matter injury assessed with magnetic resonance diffusion tensor imaging of the brain. DISCUSSION: Despite improvements in medical technology and advancements in medical science, aSAH mortality and disability rates have remained nearly unchanged for the past 10 years. Therefore, new neuroprotective strategies to attenuate the early and delayed brain injuries after aSAH are needed to reduce morbidity and mortality. TRIAL REGISTRATION: ClinicalTrials.gov NCT04696523. Registered on 6 January 2021. EudraCT, EudraCT Number: 2019-001542-17. Registered on 8 July 2020.
引用
- Laaksonen M, Rinne J, Rahi M, et al. Effect of xenon on brain injury, neurological outcome, and survival in patients after aneurysmal subarachnoid hemorrhage-study protocol for a randomized clinical trial. Trials. 2023. PMID: 37337295. doi:10.1186/s13063-023-07432-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。